N/A
Completed N=4,175
Lyrica (Pregabalin) Korean Post Marketing Surveillance Study
Source: ClinicalTrials.gov NCT01220180 ↗Enrolled (actual)
4,175
Serious AEs
0.1%
Results posted
Dec 2011
Primary outcomePrimary: Percentage of Participants Achieving 28 Days Seizure Free Period in Intent-to Treat (ITT) Population — 66.30 Percentage of participants
Summary
This study collects post-marketing safety and efficacy surveillance data in real world clinical use of pregabalin for its approved indications in Korea.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Achieving 28 Days Seizure Free Period in Intent-to Treat (ITT) Population |
66.30 | — |
| PRIMARY Percentage of Participants Achieving 28 Days Seizure Free Period in Per Protocol (PP) Population |
67.13 | — |
| PRIMARY Percentage of Participants With Improvement in Seizure Frequency in ITT Population |
55.75; 28.57; 14.13; 1.55 | — |
| PRIMARY Percentage of Participants With Improvement in Seizure Frequency in PP Population |
57.22; 29.39; 12.52; 0.87 | — |
| PRIMARY Change From Baseline in Daily Pain Score for NeP in ITT Population at Week 6 |
5.61; -3.02 | <0.0001 sig |
| PRIMARY Change From Baseline in Daily Pain Score for NeP in PP Population at Week 6 |
5.58; -3.02 | <0.0001 sig |
| PRIMARY Change From Baseline in Daily Pain Score for Fibromyalgia in ITT Population at Week 6 |
6.69; -3.37 | <0.0001 sig |
| PRIMARY Change From Baseline in Daily Pain Score for Fibromyalgia in PP Population at Week 6 |
6.69; -3.37 | <0.0001 sig |
| SECONDARY Change From Baseline in Sleep Interference Score for NeP in ITT Population at Week 6 |
4.25; -2.38 | <0.0001 sig |
| SECONDARY Change From Baseline in Sleep Interference Score for NeP in PP Population at Week 6 |
4.23; -2.37 | <0.0001 sig |
| SECONDARY Change From Baseline in Sleep Interference Score for Fibromyalgia in ITT Population at Week 6 |
6.43; -3.19 | <0.0001 sig |
| SECONDARY Change From Baseline in Sleep Interference Score for Fibromyalgia in PP Population at Week 6 |
6.41; -3.24 | <0.0001 sig |
| SECONDARY Number of Participants With Clinician's Global Impression of Change (CGIC) Scale for NeP in ITT Population |
968; 1313; 671; 141; 7; 5 | — |
| SECONDARY Number of Participants With CGIC Scale for NeP in PP Population |
956; 1306; 664; 140; 7; 5 | — |
| SECONDARY Number of Participants With Patient's Global Impression of Change (PGIC) Scale for NeP in ITT Population |
1027; 1187; 686; 195; 5; 3 | — |
| SECONDARY Number of Participants With PGIC Scale for NeP in PP Population |
1018; 1177; 680; 193; 5; 3 | — |
| SECONDARY Number of Participants With CGIC Scale for Fibromyalgia in ITT Population |
30; 62; 21; 5; 0; 0 | — |
| SECONDARY Number of Participants With CGIC Scale for Fibromyalgia in PP Population |
29; 62; 21; 5; 0; 0 | — |
| SECONDARY Number of Participants With PGIC Scale for Fibromyalgia in ITT Population |
35; 61; 14; 8; 0; 0 | — |
| SECONDARY Number of Participants With PGIC Scale for Fibromyalgia in PP Population |
34; 61; 14; 8; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Any patient treated with pregabalin for an approved indication by Korean Food and Drug Administration
Exclusion Criteria
- Non-consenting
- Hypersensitivity to the active substance or to any of the excipients
- galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Data sourced from ClinicalTrials.gov (NCT01220180). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.